MedTrace Logo

Is Glucagon-like Peptide-1 Insufficiency a Residual Risk in Coronary Artery Disease?

NCT02280837 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 190

Last updated 2021-02-10

No results posted yet for this study

Summary

In this study, the investigators hypothesized that significant proportion of patients with coronary artery disease (CAD) has reduced capacity of glucagon-like peptide-1 (GLP-1) secretion, which is detectable as blunted response of plasma active GLP-1 level to oral glucose loading and that reduced GLP-1 secretory function is associated with increased severity of coronary artery stenosis but not with classic risk factors for CAD. To test this hypothesis, the investigators will analyze correlation between GLP-1 secretory capacity and severity of coronary artery stenosis determined by Gensini Score (GS), an established score system for coronary artery stenoses. Additionally, the investigators will analyze relationship between level of "total" GLP-1 and severity of coronary artery stenosis to determine how it is different from the active GLP-1 - coronary stenosis relationship.

Conditions

Interventions

OTHER

Determination of plasma GLP-1 level

Determination of GLP-1 level in samples of oral glucose tolerance tests

Sponsors & Collaborators

Principal Investigators

  • Tetsuji Miura, MD, PhD · Sapporo Medical University

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-27
Primary Completion
2019-03-27
Completion
2020-12-29

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02280837 on ClinicalTrials.gov